Novel therapies for Cancer, Autoimmune Diseases & Inflammation

Innovimmune has a robust preclinical drug development pipeline of immunotherapeutic drugs which specifically modulate one’s own immunity that could have therapeutic benefits for patients with cancer, autoimmune diseases and chronic inflammation. We target immunocytokines and nuclear hormone receptors to power new therapeutic discoveries and develop groundbreaking immunotherapies. By stimulating the immune system, cancer patients may be better able to destroy cancer cells to improve anti-tumor activity through activation of its own host immune responses. On the other hand, attenuating hyperactive immune responses in patients with autoimmune diseases and chronic inflammation may restore immune homeostasis leading to disease resolution and cure.

We have progressed several clinical candidate selection compounds ready to enter Investigational New Drug (IND)-enabling development. Our strategic “Pipeline in a molecule” R&D approach is to advance each clinical candidate compound that has been target-validated in several preclinical Proof of Concept disease models to enter into parallel clinical development across multiple disease indications. One Drug: Multiple INDs & NDA Approvals.